Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Fuji
Cipla
AstraZeneca
Moodys
Express Scripts
Argus Health
US Army
Baxter
UBS

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,038,988

« Back to Dashboard

Which drugs does patent 8,038,988 protect, and when does it expire?


Patent 8,038,988 protects LATISSE and is included in one NDA. There has been one Paragraph IV challenge on Latisse.

This patent has fifteen patent family members in six countries.

Summary for Patent: 8,038,988

Title:Method of enhancing hair growth
Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I ##STR00001## wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R.sub.1 and R.sub.2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.
Inventor(s): Woodward; David F. (Lake Forest, CA), VanDenburgh; Amanda M. (Huntington Beach, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:11/943,714
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Allergan
LATISSE
bimatoprost
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes► Subscribe► SubscribeYY TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,038,988

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,351,404Method of enhancing hair growth► Subscribe
9,226,931Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists► Subscribe
8,926,953Method of enhancing hair growth► Subscribe
8,632,760Method of enhancing hair growth► Subscribe
8,263,054Method of enhancing hair growth► Subscribe
8,758,733Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists► Subscribe
8,986,715Method of enhancing hair growth► Subscribe
8,101,161Method of enhancing hair growth► Subscribe
8,298,518Method of enhancing hair growth► Subscribe
9,216,183Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,038,988

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2003207843► Subscribe
Australia2008203212► Subscribe
Australia2010227111► Subscribe
Australia2012261499► Subscribe
Australia2013208002► Subscribe
Canada2475106► Subscribe
European Patent Office1471876► Subscribe
European Patent Office2250996► Subscribe
European Patent Office2802331► Subscribe
Hong Kong1203839► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Boehringer Ingelheim
Chinese Patent Office
Medtronic
Harvard Business School
Covington
Queensland Health
Accenture
Mallinckrodt
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot